Home Cart Sign in  
Chemical Structure| 1152311-62-0 Chemical Structure| 1152311-62-0

Structure of Tezacaftor
CAS No.: 1152311-62-0

Chemical Structure| 1152311-62-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

VX-661 is a F508del CFTR corrector and is believed to help CFTR protein reach the cell surface.

Synonyms: VX-661

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tezacaftor

CAS No. :1152311-62-0
Formula : C26H27F3N2O6
M.W : 520.50
SMILES Code : O=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F
Synonyms :
VX-661
MDL No. :MFCD23106064
InChI Key :MJUVRTYWUMPBTR-MRXNPFEDSA-N
Pubchem ID :46199646

Safety of Tezacaftor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CFTR

In Vitro:

Cell Line
Concentration Treated Time Description References
CF monocytes 5 µM 24 h To evaluate the effect of Tezacaftor in combination with Ivacaftor on IL-18 and IL-1β levels in CF monocytes. Results showed that IVA/TEZ significantly reduced the secretion of IL-18 and IL-1β after LPS/ATP stimulation. PMC7062465
CFBE41o-(F508del) 3 μM 72 h To evaluate the effect of Tezacaftor in combination with Triple therapy on CFTR protein levels in CFBE41o-(F508del) cells, results showed that the combination of Tezacaftor with Triple therapy significantly increased total CFTR protein levels. PMC9163687

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice F508del/F508del mouse model Oral 21 mg/kg Once daily for 14 days To evaluate the effect of Tezacaftor in combination with Triple therapy on lung function in F508del/F508del mice, results showed that the combination of Tezacaftor with Triple therapy significantly improved lung function. PMC9163687

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.61mL

1.92mL

0.96mL

19.21mL

3.84mL

1.92mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories